Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$224K Buy
+891
New +$192K 0.06% 92
2026
Q1
Sell
-876
Closed -$200K 97
2025
Q4
$200K Buy
+876
New +$200K 0.06% 93
2025
Q1
Sell
-1,416
Closed -$252K 93
2024
Q4
$252K Sell
1,416
-59
-4% -$10.8K 0.1% 69
2024
Q3
$291K Sell
1,475
-120
-8% -$22.4K 0.11% 66
2024
Q2
$274K Buy
1,595
+10
+0.6% +$1.66K 0.11% 77
2024
Q1
$289K Buy
1,585
+5
+0.3% +$862 0.12% 75
2023
Q4
$245K Sell
1,580
-40
-2% -$5.83K 0.11% 76
2023
Q3
$241K Buy
1,620
+2
+0.1% +$294 0.12% 71
2023
Q2
$218K Sell
1,618
-28
-2% -$4.11K 0.1% 78
2023
Q1
$262K Sell
1,646
-38
-2% -$5.81K 0.14% 64
2022
Q4
$272K Buy
1,684
+63
+4% +$9.66K 0.16% 58
2022
Q3
$218K Buy
1,621
+26
+2% +$3.73K 0.14% 61
2022
Q2
$244K Sell
1,595
-147
-8% -$22.5K 0.15% 60
2022
Q1
$282K Buy
1,742
+143
+9% +$20.8K 0.16% 62
2021
Q4
$217K Buy
+1,599
New +$189K 0.11% 75

Other funds holding ABBV

Veery Capital's ABBV Position: Q2 2026 in Review

Veery Capital opened a new position in AbbVie (ABBV) in Q2 2026: 891 shares worth $224K. The stake represents 0.06% of the portfolio and ranks #92 among its holdings. This is a return to the name: Veery Capital previously reported a position in ABBV as recently as Q4 2025.

Veery Capital first reported a position in ABBV in Q4 2021 and has held it in 15 quarters since. The position peaked at $291K in Q3 2024. 1,265 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Veery Capital held 891 shares of AbbVie worth $224K as of Q2 2026.
  • AbbVie was a new Veery Capital position in Q2 2026.
  • AbbVie made up 0.06% of Veery Capital's portfolio in Q2 2026, its #92 holding.
  • Veery Capital first reported a position in AbbVie in Q4 2021 and has held it in 15 quarters since.
  • Veery Capital's AbbVie position peaked at $291K in Q3 2024.
  • 1,265 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Veery Capital's 13F filing for Q2 2026, filed 9 Jul 2026.